During the past decade, CH Bretagne Atlantique Vannes et Auray conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CH Bretagne Atlantique Vannes et Auray" are "Multiple Myeloma" (1 trials) and "Myeloma Multiple" (1 trials). Many other conditions were trialed in "CH Bretagne Atlantique Vannes et Auray" in a lesser frequency.

Most popular intervention types in "CH Bretagne Atlantique Vannes et Auray" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (1 trials), "Dexaméthasone" (1 trials), "Thalidomide®" (1 trials) and "Velcade®" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Bretagne Atlantique Vannes et Auray" are 2 trials for "All" genders.

Currently, there are NaN active trials in "CH Bretagne Atlantique Vannes et Auray". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in CH Bretagne Atlantique Vannes et Auray, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CH Bretagne Atlantique Vannes et Auray, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".